The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia
Open accessAbstract
The prognosis for adults with precursor B-cell acute lymphoblastic leukemia (B-ALL) remains poor, in part from a lack of therapeutic targets. We identified the type I cytokine receptor subunit CRLF2 in a functional screen for B-ALL–derived mRNA transcripts that can substitute for IL3 signaling. We demonstrate that CRLF2 is overexpressed in approximately 15% of adult and high-risk pediatric B-ALL that lack MLL, TCF3, TEL, and BCR/ABL rearrangements, but not in B-ALL with these rearrangements or other lymphoid malignancies. CRLF2 overexpression can result from translocation with the IGH locus or intrachromosomal deletion and is associated with poor outcome. CRLF2 overexpressing B-ALLs share a transcriptional signature that significantly overlaps with a BCR/ABL signature, and is enriched for genes involved in cytokine receptor and JAK-STAT signaling. In a subset of cases, CRLF2 harbors a Phe232Cys gain-of-function mutation that promotes constitutive dimerization and cytokine independent growth. A mutually exclusive subset harbors activating mutations in JAK2. In fact, all 22 B-ALLs with mutant JAK2 that we analyzed overexpress CRLF2, distinguishing CRLF2 as the key scaffold for mutant JAK2 signaling in B-ALL. Expression of WT CRLF2 with mutant JAK2 also promotes cytokine independent growth that, unlike CRLF2 Phe232Cys or ligand-induced signaling by WT CRLF2, is accompanied by JAK2 phosphorylation. Finally, cells dependent on CRLF2 signaling are sensitive to small molecule inhibitors of either JAKs or protein kinase C family kinases. Together, these findings implicate CRLF2 as an important factor in B-ALL with diagnostic, prognostic, and therapeutic implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan-Smith, E., Dalton, J. D., Girtman, K., Mathew, S., Ma, J., Pounds, S. B., et al. (2007) · Nature · doi:10.1038/nature05690 · Cited by 1,801
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422
Kanehisa, M. (2002) · Novartis Foundation Symposia · doi:10.1002/0470857897.ch8 · Cited by 1,383
BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
Mullighan, C. G., Miller, C. B., Radtke, I., Phillips, L. A., Dalton, J., Ma, J., White, D., Hughes, T. P., Le Beau, M. M., Pui, C.-H., et al. (2008) · Nature · doi:10.1038/nature06866 · Cited by 1,072 · cited 4×
“Mullighan et al. recently reported that both P2RY8-CRLF2 (22) and IKZF1 (encodes the lymphoid differentiation factor IKAROS) (2) rearrangements can also involve aberrant V(D)J recombination.”
BackgroundInfluentialActivating mutations in ALK provide a therapeutic target in neuroblastoma
George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature · doi:10.1038/nature07397 · Cited by 893
Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia
Mullighan, C. G., Phillips, L. A., Su, X., Ma, J., Miller, C. B., Shurtleff, S. A., & Downing, J. R. (2008) · Science · doi:10.1126/science.1164266 · Cited by 806
Mechanisms of chromosomal translocations in B cell lymphomas
Küppers, R., & Dalla-Favera, R. (2001) · Oncogene · doi:10.1038/sj.onc.1204640 · Cited by 660
Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia
Mullighan, C. G., Collins-Underwood, J. R., Phillips, L. A. A., Loudin, M. G., Liu, W., Zhang, J., Ma, J., Coustan-Smith, E., Harvey, R. C., Willman, C. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.469 · Cited by 623
Classification of pediatric acute lymphoblastic leukemia by gene expression profiling
Ross, M. E., Zhou, X., Song, G., Shurtleff, S. A., Girtman, K., Williams, W. K., Liu, H.-C., Mahfouz, R., Raimondi, S. C., Lenny, N., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0338 · Cited by 590
JAK mutations in high-risk childhood acute lymphoblastic leukemia
Mullighan, C. G., Zhang, J., Harvey, R. C., Collins-Underwood, J. R., Schulman, B. A., Phillips, L. A., Tasian, S. K., Loh, M. L., Su, X., Liu, W., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811761106 · Cited by 562
Russell, L. J., Capasso, M., Vater, I., Akasaka, T., Bernard, O. A., Calasanz, M. J., Chandrasekaran, T., Chapiro, E., Gesk, S., Griffiths, M., et al. (2009) · Blood · doi:10.1182/blood-2009-03-208397 · Cited by 498
Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin
Pandey, A., Ozaki, K., Baumann, H., Levin, S. D., Puel, A., Farr, A. G., Ziegler, S. F., Leonard, W. J., & Lodish, H. F. (2000) · Nature Immunology · doi:10.1038/76923 · Cited by 445
Human Thymic Stromal Lymphopoietin Preferentially Stimulates Myeloid Cells
Reche, P. A., Soumelis, V., Gorman, D. M., Clifford, T., Liu, M.-R., Travis, M., Zurawski, S. M., Johnston, J., Liu, Y.-J., Spits, H., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.1.336 · Cited by 403
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome
Bercovich, D., Ganmore, I., Scott, L. M., Wainreb, G., Birger, Y., Elimelech, A., Shochat, C., Cazzaniga, G., Biondi, A., Basso, G., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61341-0 · Cited by 337
Clinical Significance of Cytogenetic Abnormalities in Adult Acute Lymphoblastic Leukemia
Faderl, S., Kantarjian, H. M., Talpaz, M., & Estrov, Z. (1998) · Blood · doi:10.1182/blood.v91.11.3995 · Cited by 335
Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D. G., & Lodish, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509714102 · Cited by 316
Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia
Mullighan, C. G., Phillips, L. A., Su, X., Ma, J., Miller, C. B., & Downing, J. R. (2008) · Blood · doi:10.1182/blood.v112.11.429.429 · Cited by 309
Levin, S. D., Koelling, R. M., Friend, S. L., Isaksen, D. E., Ziegler, S. F., Perlmutter, R. M., & Farr, A. G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.2.677 · Cited by 237
Akasaka, T., Balasas, T., Russell, L. J., Sugimoto, K.-J., Majid, A., Walewska, R., Karran, E. L., Brown, D. G., Cain, K., Harder, L., et al. (2007) · Blood · doi:10.1182/blood-2006-08-041012 · Cited by 215
Slupianek, A., Hoser, G., Majsterek, I., Bronisz, A., Malecki, M., Blasiak, J., Fishel, R., & Skorski, T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.12.4189-4201.2002 · Cited by 207
STAT signaling in the pathogenesis and treatment of leukemias
Lin, T. S., Mahajan, S., & Frank, D. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203486 · Cited by 205
Self-citationKearney, L., Gonzalez De Castro, D., Yeung, J., Procter, J., Horsley, S. W., Eguchi-Ishimae, M., Bateman, C. M., Anderson, K., Chaplin, T., Young, B. D., et al. (2009) · Blood · doi:10.1182/blood-2008-08-170928 · Cited by 188
Self-citationJiang, J., Greulich, H., Jänne, P. A., Sellers, W. R., Meyerson, M., & Griffin, J. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1829 · Cited by 186
Self-citationDemehri, S., Liu, Z., Lee, J., Lin, M.-H., Crosby, S. D., Roberts, C. J., Grigsby, P. W., Miner, J. H., Farr, A. G., & Kopan, R. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060123 · Cited by 174
Chiaretti, S., Li, X., Gentleman, R. C., Vitale, A., Wang, K. S., Mandelli, F., Foà, R., & Ritz, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2165 · Cited by 158
Self-citationActivating mutations in human acute megakaryoblastic leukemia
Malinge, S., Ragu, C., Della-Valle, V., Pisani, D. F., Constantinescu, S. N., Pérez, C., Villeval, J., Reinhardt, D., Landman‐Parker, J., Michaux, L., et al. (2008) · Blood · doi:10.1182/blood-2008-01-136366 · Cited by 145
Shimamura, T., Ji, H., Minami, Y., Thomas, R. K., Lowell, A. M., Shah, K., Greulich, H. E., Glatt, K. A., Meyerson, M. M., Shapiro, G. I., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0971 · Cited by 141
Mechanisms promoting translocations in editing and switching peripheral B cells
Wang, J. H., Gostissa, M., Yan, C. T., Goff, P. H., Hickernell, T. R., Hansen, E., Difilippantonio, S., Wesemann, D. R., Zarrin, A. A., Rajewsky, K., et al. (2009) · Nature · doi:10.1038/nature08159 · Cited by 133
Malinge, S., Abdelali, R. B., Settegrana, C., Radford‐Weiss, I., Debré, M., Beldjord, K., Macintyre, E. A., Villeval, J., Vainchenker, W., Berger, R., et al. (2006) · Blood · doi:10.1182/blood-2006-09-045963 · Cited by 126
Juric, D., Lacayo, N. J., Ramsey, M. C., Racevskis, J., Wiernik, P. H., Rowe, J. M., Goldstone, A. H., O'Dwyer, P. J., Paietta, E. M., & Sikic, B. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3534 · Cited by 122
Chapter 1 TSLP in Epithelial Cell and Dendritic Cell Cross Talk
Liu, Y. (2009) · Advances in immunology · doi:10.1016/s0065-2776(08)01001-8 · Cited by 117
Prognostic Implications of Gene Mutations in Acute Myeloid Leukemia With Normal Cytogenetics
Gaidzik, V. I., & Döhner, K. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.005 · Cited by 110
Fine, B. M., Stanulla, M., Schrappe, M., Ho, M., Viehmann, S. F., Harbott, J., & Boxer, L. M. (2003) · Blood · doi:10.1182/blood-2003-05-1518 · Cited by 108
Identification of gene expression profiles that segregate patients with childhood leukemia.
Moos, P. J., Raetz, E. A., Carlson, M. A., Szabó, A., Smith, F. E., Willman, C. L., Wei, Q., Hunger, S. P., & Carroll, W. L. (2002) · PubMed · Cited by 96
Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia
Gaikwad, A. S., Rye, C. L., Devidas, M., Heerema, N. A., Carroll, A. J., Izraeli, S., Plon, S. E., Basso, G., Pession, A., & Rabin, K. R. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07552.x · Cited by 93
Brown, V. I., Hulitt, J., Fish, J. D., Sheen, C., Bruno, M., Xu, Q., Carroll, M. P., Fang, J., Teachey, D. T., & Grupp, S. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4704 · Cited by 62
First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults
Ottmann, O. G., & Pfeifer, H. (2009) · Current Opinion in Oncology · doi:10.1097/01.cco.0000357476.43164.6b · Cited by 54
Cited by
Inaba, H., Greaves, M., & Mullighan, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62187-4 · Cited by 1,074
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Roberts, K. G., Morin, R. D., Zhang, J., Hirst, M., Zhao, Y., Su, X., Chen, S.-C., Payne-Turner, D., Churchman, M. L., Harvey, R. C., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.005 · Cited by 714
Harnessing the biology of IL-7 for therapeutic application
Mackall, C. L., Fry, T. J., & Gress, R. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2970 · Cited by 571
Genetic Basis of Acute Lymphoblastic Leukemia
Iacobucci, I., & Mullighan, C. G. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7836 · Cited by 556
Metadata
- Authors
- Yoda, A., Yoda, Y., Chiaretti, S., Bar-Natan, M., Mani, K., Rodig, S. J., West, N., Xiao, Y., Brown, J. R., Mitsiades, C., Sattler, M., Kutok, J. L., DeAngelo, D. J., Wadleigh, M., Piciocchi, A., Dal Cin, P., Bradner, J. E., Griffin, J. D., Anderson, K. C., Stone, R. M., Ritz, J., Foà, R., Aster, J. C., Frank, D. A., & Weinstock, D. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-12-29
- Volume
- 107
- Issue
- 1
- Pages
- 252-257
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2036999612
- Cited by
- 340
- References
- 37
- FWCI
- 27.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.